Artivion (NYSE:AORT) SVP Sells $27,834.73 in Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 977 shares of the stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the completion of the sale, the senior vice president owned 184,118 shares of the company’s stock, valued at $5,245,521.82. The trade was a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Artivion Stock Up 2.8%

Shares of NYSE:AORT opened at $29.22 on Friday. The firm has a market cap of $1.42 billion, a P/E ratio of -417.33 and a beta of 1.25. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25. The business has a fifty day simple moving average of $24.28 and a 200 day simple moving average of $30.59. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The firm had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%. Analysts predict that Artivion, Inc. will post 0.45 earnings per share for the current year.

Hedge Funds Weigh In On Artivion

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of Artivion in the 2nd quarter valued at about $149,965,000. Conestoga Capital Advisors LLC acquired a new position in Artivion during the 1st quarter worth approximately $43,044,000. Summit Partners Public Asset Management LLC bought a new position in Artivion in the fourth quarter worth approximately $39,401,000. Invesco Ltd. boosted its holdings in Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock worth $50,228,000 after acquiring an additional 748,119 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its holdings in Artivion by 144.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 537,375 shares of the company’s stock worth $24,510,000 after acquiring an additional 317,518 shares in the last quarter. Institutional investors own 86.37% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on AORT. Weiss Ratings lowered shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a report on Tuesday. Canaccord Genuity Group set a $39.00 price objective on shares of Artivion in a research note on Friday, August 7th. Needham & Company LLC reiterated a “buy” rating and set a $44.00 price objective on shares of Artivion in a research report on Monday, July 20th. Citizens Jmp lowered their target price on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a research note on Friday, May 8th. Finally, Citigroup restated a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Artivion currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.67.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.